Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1223Neoplasms 1028Carcinoma, Non-Small-Cell Lung 747Prostatic Neoplasms 693Colorectal Neoplasms 591Lung Neoplasms 576Leukemia, Myeloid, Acute 396Pancreatic Neoplasms 395Neoplasm Metastasis 389Ovarian Neoplasms 369Multiple Myeloma 369Stomach Neoplasms 318Carcinoma, Hepatocellular 303Melanoma 283Brain Neoplasms 281Recurrence 274Squamous Cell Carcinoma of Head and Neck 266Head and Neck Neoplasms 239Glioblastoma 235Endometrial Neoplasms 232Triple Negative Breast Neoplasms 230Lymphoma 223Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Uterine Cervical Neoplasms 221Sarcoma 202Hematologic Neoplasms 202Urinary Bladder Neoplasms 198Esophageal Neoplasms 190Carcinoma, Renal Cell 188Lymphoma, Non-Hodgkin 176

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Primary Malignant Peripheral Nerve Sheath Tumors × 1 year × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡